Skip to main content
. 2014 Dec 11;6(4):2164–2179. doi: 10.18632/oncotarget.2941

Figure 6. Cancerous inhibitor of protein phosphatase 2A (CIP2A) expression in 49 non-small cell lung cancer patients.

Figure 6

(A) Strong, moderate, weak, and negative expressions of Elk-1, CIP2A, and p-AKT. (B) Elk-1 and CIP2A expression in the non-tumor part and tumor part; *, p < 0.05. (C) The correlation of Elk-1 and CIP2A, r= 0.773, p <0.001. (D) Kaplan-Meier estimates of progression-free survival in the 49 patients with NSCLC according to high or low CIP2A expression. (E) Schema of the molecular mechanism of afatinib on the Elk-1/CIP2A/PP2A/AKT pathway.